GSK's (GSK) "Hold" Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their hold rating on shares of GSK (LON:GSK - Free Report) in a research report sent to investors on Friday morning, MarketBeat Ratings reports. Berenberg Bank currently has a GBX 1,600 ($21.46) price objective on the stock.

GSK has been the topic of a number of other research reports. Shore Capital restated a "buy" rating on shares of GSK in a report on Wednesday, April 30th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 1,450 ($19.45) target price on shares of GSK in a report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Friday.

GSK Trading Down 0.1%

Shares of GSK stock traded down GBX 2 ($0.03) during mid-day trading on Friday, reaching GBX 1,346 ($18.05). The company's stock had a trading volume of 1,683,255,125 shares, compared to its average volume of 25,790,002. GSK has a 12-month low of GBX 1,242.50 ($16.67) and a 12-month high of GBX 1,678.68 ($22.52). The firm has a market capitalization of £54.62 billion, a PE ratio of 21.74, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The company's 50 day simple moving average is GBX 1,435.32 and its 200-day simple moving average is GBX 1,423.08.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, research analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Emma Walmsley sold 5,473 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.44), for a total transaction of £79,303.77 ($106,376.62). Also, insider Jonathan Symonds purchased 1,350 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average cost of GBX 1,435 ($19.25) per share, with a total value of £19,372.50 ($25,985.92). Over the last three months, insiders purchased 1,905 shares of company stock valued at $2,732,835. Insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.